Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||
Goods sale service render cash | 5.16%589.96M | 3.20%2.57B | -6.63%1.91B | -4.74%1.14B | -20.97%561.01M | 11.40%2.49B | 3.35%2.04B | 1.79%1.2B | 19.63%709.91M | 34.07%2.24B |
Refunds of taxes and levies | 2.39%3.55M | 957.35%53.34M | 190.61%13.33M | 125.65%7.5M | 429.85%3.47M | -82.10%5.04M | -84.32%4.59M | -87.23%3.32M | -68.83%655K | -27.28%28.19M |
Cash received relating to other operating activities | 188.78%55.74M | -28.42%244.54M | -37.09%61.35M | 14.19%30.23M | 23.68%19.3M | 7.00%341.64M | 81.69%97.53M | -12.95%26.47M | -21.07%15.61M | 86.86%319.28M |
Cash inflows from operating activities | 11.22%649.26M | 1.09%2.87B | -7.59%1.98B | -3.98%1.18B | -19.61%583.78M | 9.84%2.84B | 4.14%2.15B | -0.45%1.23B | 18.02%726.17M | 37.61%2.58B |
Goods services cash paid | 49.80%453.47M | -1.65%1.9B | -15.06%1.38B | -1.17%780.63M | -21.97%302.71M | -1.85%1.93B | -4.83%1.63B | -18.16%789.91M | -2.03%387.94M | 69.68%1.97B |
Staff behalf paid | -13.16%100.26M | 17.09%413.43M | 18.55%283.88M | 23.22%199.05M | 29.80%115.45M | 1.84%353.09M | -1.07%239.47M | -2.54%161.54M | -2.78%88.95M | 37.23%346.7M |
All taxes paid | 29.73%19.9M | 49.67%39.49M | -3.88%28.67M | -1.04%19.95M | 10.63%15.34M | -16.42%26.38M | -23.15%29.83M | -29.82%20.16M | -38.43%13.86M | 135.20%31.57M |
Cash paid relating to other operating activities | 156.72%59.91M | -43.56%204.31M | 19.16%102.37M | 1.83%64.67M | -26.48%23.33M | 52.50%361.99M | -1.96%85.91M | 54.09%63.51M | 2.21%31.74M | -23.58%237.37M |
Cash outflows from operating activities | 38.68%633.54M | -4.34%2.55B | -9.35%1.8B | 2.82%1.06B | -12.57%456.84M | 3.46%2.67B | -4.61%1.98B | -13.81%1.04B | -3.43%522.49M | 48.77%2.58B |
Net cash flows from operating activities | -87.62%15.72M | 88.06%313.53M | 13.89%185.24M | -40.15%116.53M | -37.67%126.95M | 7,896.77%166.71M | 972.63%162.66M | 464.89%194.71M | 174.23%203.68M | -98.53%2.08M |
Investing cash flow | ||||||||||
Cash received from disposal of investments | ---- | ---- | ---- | ---- | ---- | 405.94%20M | --20M | --20M | --20M | -77.62%3.95M |
Cash received from returns on investments | 69,192.56%13.56M | -88.41%1.84M | 123.87%360.88K | -66.51%40.46K | -83.80%19.57K | 41.33%15.89M | -88.22%161.2K | -90.51%120.81K | -61.01%120.81K | 217.85%11.24M |
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -15.50%440K | 116.30%12.08M | 563.30%16.7M | 50.41%3.68M | -77.74%520.71K | -60.74%5.58M | -65.52%2.52M | -62.57%2.45M | -16.93%2.34M | -96.78%14.22M |
Net cash received from disposal of subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | --45.55M | --35.82M | --35.82M | --23.82M | ---- |
Cash received relating to other investing activities | 209.91%57.33M | 50.97%224.67M | -53.92%108.08M | 175.41%129.38M | -49.08%18.5M | -77.83%148.81M | -64.28%234.56M | -89.53%46.98M | -87.83%36.33M | -13.71%671.35M |
Cash inflows from investing activities | 274.65%71.33M | 1.16%238.59M | -57.30%125.14M | 26.32%133.1M | -76.95%19.04M | -66.35%235.84M | -55.95%293.06M | -76.91%105.37M | -72.62%82.61M | -43.52%700.77M |
Cash paid to acquire fixed assets intangible assets and other long-term assets | 70.97%72.7M | -10.98%290.6M | -45.15%155.29M | -66.27%82.28M | -66.36%42.53M | -56.38%326.43M | -25.20%283.09M | 4.75%243.91M | 0.08%126.42M | 188.35%748.36M |
Cash paid to acquire investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --8.03M |
Net cash paid to acquire subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 134.91%18.15M |
Cash paid relating to other investing activities | -23.04%25.38M | 23.50%195.04M | -60.13%96.32M | -39.16%133.97M | -78.56%32.98M | -74.94%157.93M | -61.88%241.57M | -56.85%220.19M | -60.27%153.81M | -23.18%630.2M |
Cash outflows from investing activities | 29.90%98.08M | 0.26%485.64M | -52.04%251.61M | -53.41%216.25M | -73.06%75.5M | -65.52%484.36M | -49.43%524.66M | -39.61%464.1M | -48.47%280.23M | 29.16%1.4B |
Net cash flows from investing activities | 52.63%-26.75M | 0.59%-247.05M | 45.39%-126.47M | 76.82%-83.15M | 71.43%-56.46M | 64.70%-248.52M | 37.77%-231.6M | -14.92%-358.73M | 18.38%-197.62M | -559.72%-703.97M |
Financing cash flow | ||||||||||
Cash received from capital contributions | ---- | --400K | ---- | ---- | 85.03%-154K | ---- | ---- | ---- | -123.83%-1.03M | ---- |
-Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | --400K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from borrowing | 55.28%114.67M | -7.39%548.11M | -28.57%340.11M | -25.04%195.85M | -7.49%73.85M | 2.41%591.82M | 27.71%476.18M | 85.28%261.29M | -24.71%79.83M | 93.04%577.91M |
Cash received relating to other financing activities | ---- | --11.73M | ---- | ---- | ---- | ---- | -99.92%30.31K | ---- | ---- | 237.15%194.2M |
Cash inflows from financing activities | 55.60%114.67M | -5.34%560.24M | -28.58%340.11M | -25.04%195.85M | -6.47%73.7M | -23.35%591.82M | 15.37%476.21M | 44.40%261.29M | -29.81%78.8M | 66.19%772.11M |
Borrowing repayment | 60.55%96.39M | 13.39%415.03M | 35.18%309.66M | 182.54%174.68M | 56.31%60.04M | 156.66%366.02M | 104.03%229.08M | 168.69%61.82M | 125.93%38.41M | -69.08%142.6M |
Dividend interest payment | 4.58%7.56M | 17.14%31.18M | 86.01%22.13M | 62.05%14.66M | 82.52%7.23M | 145.64%26.62M | 155.61%11.9M | 259.34%9.05M | 285.92%3.96M | 7.49%10.84M |
Cash payments relating to other financing activities | ---- | 23.84%148.23M | -5.63%71.84M | 24.06%61.46M | 6.76%26.47M | 143.17%119.69M | 202.59%76.13M | 187.32%49.54M | 341.40%24.8M | -3.49%49.22M |
Cash outflows from financing activities | 10.89%103.94M | 16.03%594.43M | 27.29%403.64M | 108.28%250.81M | 39.56%93.74M | 152.80%512.32M | 123.17%317.11M | 181.54%120.42M | 184.07%67.17M | -61.20%202.66M |
Net cash flows from financing activities | 153.53%10.73M | -143.01%-34.19M | -139.93%-63.53M | -139.01%-54.96M | -272.30%-20.04M | -86.04%79.49M | -41.22%159.1M | 1.95%140.87M | -86.88%11.63M | 1,086.70%569.45M |
Net cash flow | ||||||||||
Exchange rate change effecting cash and cash equivalents | 143.49%294.15K | -534.82%-4.46M | -104.93%-57.14K | -138.14%-671.31K | -138.66%-676.31K | -53.37%1.03M | -74.51%1.16M | -27.59%1.76M | -1,156.03%-283.37K | 143.19%2.2M |
Net increase in cash and cash equivalents | -100.01%-7.03K | 2,255.49%27.82M | -105.27%-4.81M | -3.99%-22.25M | 185.76%49.77M | 99.01%-1.29M | 179.02%91.32M | 84.40%-21.39M | 121.98%17.42M | -156.02%-130.23M |
Add:Begin period cash and cash equivalents | 12.98%242.11M | -0.60%214.29M | -0.60%214.29M | -0.60%214.29M | -0.60%214.29M | -37.66%215.58M | -37.66%215.58M | -37.66%215.58M | -37.66%215.58M | 205.13%345.81M |
End period cash equivalent | -8.31%242.1M | 12.98%242.11M | -31.74%209.48M | -1.10%192.05M | 13.33%264.06M | -0.60%214.29M | 33.29%306.9M | -6.96%194.19M | -12.60%233M | -37.66%215.58M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion with explanatory notes | -- | -- | -- | Unqualified opinion |
Auditor | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.